Auto-populated list of related Clinical Trials
(Breast, Cleft Lip and Palate, Hand, Lymphedema, Oral, Skin, Trauma)

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

This study has two parts.

Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents.

Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types.

In Part 2, the same participants will continue to receive pexidartinib twice daily.

Participants will be allowed to continue using pexidartinib as long as the participant derives benefit.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Daiichi Sankyo, Inc.

Intervention(s):

  • Drug: Tolbutamide
  • Drug: Midazolam
  • Drug: Pexidartinib

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Is the age of majority in country of residence

   - Has a diagnosis of:

      1. tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity
      or functional limitations and for whom surgery is not an option (prior
      pexidartinib is permitted for TGCT patients unless ineffective or not tolerated
      and there has been a washout period of at least 4 weeks)

      2. KIT-mutant tumor, including melanoma or gastrointestinal stromal tumor (GIST),
      for which there is no standard systemic therapy, or

      3. other solid tumors (all comers) for which there is no standard systemic therapy
      and there is a rationale for use of pexidartinib at the Investigator's discretion

   - If a female of childbearing potential, had a negative serum pregnancy test within 14
   days before enrollment, or within 72 hours before enrollment where required

   - Is a non-sterile male or female willing to use of one of the protocol-defined highly
   effective contraception methods:

      1. intra-uterine device (nonhormonal or hormonal)

      2. sexual abstinence (only if this is in line with the patient's current lifestyle)

      3. barrier methods (eg, condom, diaphragm) used in combination with hormonal methods
      associated with inhibition of ovulation

   - Is a surgically sterile male or female, or is postmenopausal for at least 1 year, at
   least 50 years of age, with a follicle-stimulating hormone level > 40
   milli-International units per mL (mIU/mL)

   - Has adequate hematologic, hepatic, and renal function as defined by the protocol

   - Is able and willing to follow all study procedures

   - Has provided a signed informed consent

Exclusion Criteria:

   - Is pregnant or breastfeeding

   - Is unable to swallow oral medication

   - Is unable to follow study procedures

   - Is taking or has taken any medications or therapies outside of protocol-defined
   parameters

   - Has any disease or condition that, per protocol or in the opinion of the investigator,
   might affect:

      1. safety and well-being of the participant or offspring

      2. safety of study staff

      3. analysis of results

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

This study has two parts.

Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents.

Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types.

In Part 2, the same participants will continue to receive pexidartinib twice daily.

Participants will be allowed to continue using pexidartinib as long as the participant derives benefit.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Daiichi Sankyo, Inc.

Intervention(s):

  • Drug: Tolbutamide
  • Drug: Midazolam
  • Drug: Pexidartinib

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Is the age of majority in country of residence

   - Has a diagnosis of:

      1. tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity
      or functional limitations and for whom surgery is not an option (prior
      pexidartinib is permitted for TGCT patients unless ineffective or not tolerated
      and there has been a washout period of at least 4 weeks)

      2. KIT-mutant tumor, including melanoma or gastrointestinal stromal tumor (GIST),
      for which there is no standard systemic therapy, or

      3. other solid tumors (all comers) for which there is no standard systemic therapy
      and there is a rationale for use of pexidartinib at the Investigator's discretion

   - If a female of childbearing potential, had a negative serum pregnancy test within 14
   days before enrollment, or within 72 hours before enrollment where required

   - Is a non-sterile male or female willing to use of one of the protocol-defined highly
   effective contraception methods:

      1. intra-uterine device (nonhormonal or hormonal)

      2. sexual abstinence (only if this is in line with the patient's current lifestyle)

      3. barrier methods (eg, condom, diaphragm) used in combination with hormonal methods
      associated with inhibition of ovulation

   - Is a surgically sterile male or female, or is postmenopausal for at least 1 year, at
   least 50 years of age, with a follicle-stimulating hormone level > 40
   milli-International units per mL (mIU/mL)

   - Has adequate hematologic, hepatic, and renal function as defined by the protocol

   - Is able and willing to follow all study procedures

   - Has provided a signed informed consent

Exclusion Criteria:

   - Is pregnant or breastfeeding

   - Is unable to swallow oral medication

   - Is unable to follow study procedures

   - Is taking or has taken any medications or therapies outside of protocol-defined
   parameters

   - Has any disease or condition that, per protocol or in the opinion of the investigator,
   might affect:

      1. safety and well-being of the participant or offspring

      2. safety of study staff

      3. analysis of results

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

This study has two parts.

Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents.

Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types.

In Part 2, the same participants will continue to receive pexidartinib twice daily.

Participants will be allowed to continue using pexidartinib as long as the participant derives benefit.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Daiichi Sankyo, Inc.

Intervention(s):

  • Drug: Tolbutamide
  • Drug: Midazolam
  • Drug: Pexidartinib

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Is the age of majority in country of residence

   - Has a diagnosis of:

      1. tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity
      or functional limitations and for whom surgery is not an option (prior
      pexidartinib is permitted for TGCT patients unless ineffective or not tolerated
      and there has been a washout period of at least 4 weeks)

      2. KIT-mutant tumor, including melanoma or gastrointestinal stromal tumor (GIST),
      for which there is no standard systemic therapy, or

      3. other solid tumors (all comers) for which there is no standard systemic therapy
      and there is a rationale for use of pexidartinib at the Investigator's discretion

   - If a female of childbearing potential, had a negative serum pregnancy test within 14
   days before enrollment, or within 72 hours before enrollment where required

   - Is a non-sterile male or female willing to use of one of the protocol-defined highly
   effective contraception methods:

      1. intra-uterine device (nonhormonal or hormonal)

      2. sexual abstinence (only if this is in line with the patient's current lifestyle)

      3. barrier methods (eg, condom, diaphragm) used in combination with hormonal methods
      associated with inhibition of ovulation

   - Is a surgically sterile male or female, or is postmenopausal for at least 1 year, at
   least 50 years of age, with a follicle-stimulating hormone level > 40
   milli-International units per mL (mIU/mL)

   - Has adequate hematologic, hepatic, and renal function as defined by the protocol

   - Is able and willing to follow all study procedures

   - Has provided a signed informed consent

Exclusion Criteria:

   - Is pregnant or breastfeeding

   - Is unable to swallow oral medication

   - Is unable to follow study procedures

   - Is taking or has taken any medications or therapies outside of protocol-defined
   parameters

   - Has any disease or condition that, per protocol or in the opinion of the investigator,
   might affect:

      1. safety and well-being of the participant or offspring

      2. safety of study staff

      3. analysis of results

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

This study has two parts.

Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents.

Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types.

In Part 2, the same participants will continue to receive pexidartinib twice daily.

Participants will be allowed to continue using pexidartinib as long as the participant derives benefit.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Daiichi Sankyo, Inc.

Intervention(s):

  • Drug: Tolbutamide
  • Drug: Midazolam
  • Drug: Pexidartinib

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Is the age of majority in country of residence

   - Has a diagnosis of:

      1. tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity
      or functional limitations and for whom surgery is not an option (prior
      pexidartinib is permitted for TGCT patients unless ineffective or not tolerated
      and there has been a washout period of at least 4 weeks)

      2. KIT-mutant tumor, including melanoma or gastrointestinal stromal tumor (GIST),
      for which there is no standard systemic therapy, or

      3. other solid tumors (all comers) for which there is no standard systemic therapy
      and there is a rationale for use of pexidartinib at the Investigator's discretion

   - If a female of childbearing potential, had a negative serum pregnancy test within 14
   days before enrollment, or within 72 hours before enrollment where required

   - Is a non-sterile male or female willing to use of one of the protocol-defined highly
   effective contraception methods:

      1. intra-uterine device (nonhormonal or hormonal)

      2. sexual abstinence (only if this is in line with the patient's current lifestyle)

      3. barrier methods (eg, condom, diaphragm) used in combination with hormonal methods
      associated with inhibition of ovulation

   - Is a surgically sterile male or female, or is postmenopausal for at least 1 year, at
   least 50 years of age, with a follicle-stimulating hormone level > 40
   milli-International units per mL (mIU/mL)

   - Has adequate hematologic, hepatic, and renal function as defined by the protocol

   - Is able and willing to follow all study procedures

   - Has provided a signed informed consent

Exclusion Criteria:

   - Is pregnant or breastfeeding

   - Is unable to swallow oral medication

   - Is unable to follow study procedures

   - Is taking or has taken any medications or therapies outside of protocol-defined
   parameters

   - Has any disease or condition that, per protocol or in the opinion of the investigator,
   might affect:

      1. safety and well-being of the participant or offspring

      2. safety of study staff

      3. analysis of results

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

This study has two parts.

Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents.

Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types.

In Part 2, the same participants will continue to receive pexidartinib twice daily.

Participants will be allowed to continue using pexidartinib as long as the participant derives benefit.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Daiichi Sankyo, Inc.

Intervention(s):

  • Drug: Tolbutamide
  • Drug: Midazolam
  • Drug: Pexidartinib

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Is the age of majority in country of residence

   - Has a diagnosis of:

      1. tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity
      or functional limitations and for whom surgery is not an option (prior
      pexidartinib is permitted for TGCT patients unless ineffective or not tolerated
      and there has been a washout period of at least 4 weeks)

      2. KIT-mutant tumor, including melanoma or gastrointestinal stromal tumor (GIST),
      for which there is no standard systemic therapy, or

      3. other solid tumors (all comers) for which there is no standard systemic therapy
      and there is a rationale for use of pexidartinib at the Investigator's discretion

   - If a female of childbearing potential, had a negative serum pregnancy test within 14
   days before enrollment, or within 72 hours before enrollment where required

   - Is a non-sterile male or female willing to use of one of the protocol-defined highly
   effective contraception methods:

      1. intra-uterine device (nonhormonal or hormonal)

      2. sexual abstinence (only if this is in line with the patient's current lifestyle)

      3. barrier methods (eg, condom, diaphragm) used in combination with hormonal methods
      associated with inhibition of ovulation

   - Is a surgically sterile male or female, or is postmenopausal for at least 1 year, at
   least 50 years of age, with a follicle-stimulating hormone level > 40
   milli-International units per mL (mIU/mL)

   - Has adequate hematologic, hepatic, and renal function as defined by the protocol

   - Is able and willing to follow all study procedures

   - Has provided a signed informed consent

Exclusion Criteria:

   - Is pregnant or breastfeeding

   - Is unable to swallow oral medication

   - Is unable to follow study procedures

   - Is taking or has taken any medications or therapies outside of protocol-defined
   parameters

   - Has any disease or condition that, per protocol or in the opinion of the investigator,
   might affect:

      1. safety and well-being of the participant or offspring

      2. safety of study staff

      3. analysis of results

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

This study has two parts.

Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents.

Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types.

In Part 2, the same participants will continue to receive pexidartinib twice daily.

Participants will be allowed to continue using pexidartinib as long as the participant derives benefit.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Daiichi Sankyo, Inc.

Intervention(s):

  • Drug: Tolbutamide
  • Drug: Midazolam
  • Drug: Pexidartinib

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Is the age of majority in country of residence

   - Has a diagnosis of:

      1. tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity
      or functional limitations and for whom surgery is not an option (prior
      pexidartinib is permitted for TGCT patients unless ineffective or not tolerated
      and there has been a washout period of at least 4 weeks)

      2. KIT-mutant tumor, including melanoma or gastrointestinal stromal tumor (GIST),
      for which there is no standard systemic therapy, or

      3. other solid tumors (all comers) for which there is no standard systemic therapy
      and there is a rationale for use of pexidartinib at the Investigator's discretion

   - If a female of childbearing potential, had a negative serum pregnancy test within 14
   days before enrollment, or within 72 hours before enrollment where required

   - Is a non-sterile male or female willing to use of one of the protocol-defined highly
   effective contraception methods:

      1. intra-uterine device (nonhormonal or hormonal)

      2. sexual abstinence (only if this is in line with the patient's current lifestyle)

      3. barrier methods (eg, condom, diaphragm) used in combination with hormonal methods
      associated with inhibition of ovulation

   - Is a surgically sterile male or female, or is postmenopausal for at least 1 year, at
   least 50 years of age, with a follicle-stimulating hormone level > 40
   milli-International units per mL (mIU/mL)

   - Has adequate hematologic, hepatic, and renal function as defined by the protocol

   - Is able and willing to follow all study procedures

   - Has provided a signed informed consent

Exclusion Criteria:

   - Is pregnant or breastfeeding

   - Is unable to swallow oral medication

   - Is unable to follow study procedures

   - Is taking or has taken any medications or therapies outside of protocol-defined
   parameters

   - Has any disease or condition that, per protocol or in the opinion of the investigator,
   might affect:

      1. safety and well-being of the participant or offspring

      2. safety of study staff

      3. analysis of results

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

This study has two parts.

Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents.

Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types.

In Part 2, the same participants will continue to receive pexidartinib twice daily.

Participants will be allowed to continue using pexidartinib as long as the participant derives benefit.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Daiichi Sankyo, Inc.

Intervention(s):

  • Drug: Tolbutamide
  • Drug: Midazolam
  • Drug: Pexidartinib

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Is the age of majority in country of residence

   - Has a diagnosis of:

      1. tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity
      or functional limitations and for whom surgery is not an option (prior
      pexidartinib is permitted for TGCT patients unless ineffective or not tolerated
      and there has been a washout period of at least 4 weeks)

      2. KIT-mutant tumor, including melanoma or gastrointestinal stromal tumor (GIST),
      for which there is no standard systemic therapy, or

      3. other solid tumors (all comers) for which there is no standard systemic therapy
      and there is a rationale for use of pexidartinib at the Investigator's discretion

   - If a female of childbearing potential, had a negative serum pregnancy test within 14
   days before enrollment, or within 72 hours before enrollment where required

   - Is a non-sterile male or female willing to use of one of the protocol-defined highly
   effective contraception methods:

      1. intra-uterine device (nonhormonal or hormonal)

      2. sexual abstinence (only if this is in line with the patient's current lifestyle)

      3. barrier methods (eg, condom, diaphragm) used in combination with hormonal methods
      associated with inhibition of ovulation

   - Is a surgically sterile male or female, or is postmenopausal for at least 1 year, at
   least 50 years of age, with a follicle-stimulating hormone level > 40
   milli-International units per mL (mIU/mL)

   - Has adequate hematologic, hepatic, and renal function as defined by the protocol

   - Is able and willing to follow all study procedures

   - Has provided a signed informed consent

Exclusion Criteria:

   - Is pregnant or breastfeeding

   - Is unable to swallow oral medication

   - Is unable to follow study procedures

   - Is taking or has taken any medications or therapies outside of protocol-defined
   parameters

   - Has any disease or condition that, per protocol or in the opinion of the investigator,
   might affect:

      1. safety and well-being of the participant or offspring

      2. safety of study staff

      3. analysis of results

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

This study has two parts.

Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents.

Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types.

In Part 2, the same participants will continue to receive pexidartinib twice daily.

Participants will be allowed to continue using pexidartinib as long as the participant derives benefit.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Daiichi Sankyo, Inc.

Intervention(s):

  • Drug: Tolbutamide
  • Drug: Midazolam
  • Drug: Pexidartinib

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Is the age of majority in country of residence

   - Has a diagnosis of:

      1. tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity
      or functional limitations and for whom surgery is not an option (prior
      pexidartinib is permitted for TGCT patients unless ineffective or not tolerated
      and there has been a washout period of at least 4 weeks)

      2. KIT-mutant tumor, including melanoma or gastrointestinal stromal tumor (GIST),
      for which there is no standard systemic therapy, or

      3. other solid tumors (all comers) for which there is no standard systemic therapy
      and there is a rationale for use of pexidartinib at the Investigator's discretion

   - If a female of childbearing potential, had a negative serum pregnancy test within 14
   days before enrollment, or within 72 hours before enrollment where required

   - Is a non-sterile male or female willing to use of one of the protocol-defined highly
   effective contraception methods:

      1. intra-uterine device (nonhormonal or hormonal)

      2. sexual abstinence (only if this is in line with the patient's current lifestyle)

      3. barrier methods (eg, condom, diaphragm) used in combination with hormonal methods
      associated with inhibition of ovulation

   - Is a surgically sterile male or female, or is postmenopausal for at least 1 year, at
   least 50 years of age, with a follicle-stimulating hormone level > 40
   milli-International units per mL (mIU/mL)

   - Has adequate hematologic, hepatic, and renal function as defined by the protocol

   - Is able and willing to follow all study procedures

   - Has provided a signed informed consent

Exclusion Criteria:

   - Is pregnant or breastfeeding

   - Is unable to swallow oral medication

   - Is unable to follow study procedures

   - Is taking or has taken any medications or therapies outside of protocol-defined
   parameters

   - Has any disease or condition that, per protocol or in the opinion of the investigator,
   might affect:

      1. safety and well-being of the participant or offspring

      2. safety of study staff

      3. analysis of results

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

This study has two parts.

Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents.

Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types.

In Part 2, the same participants will continue to receive pexidartinib twice daily.

Participants will be allowed to continue using pexidartinib as long as the participant derives benefit.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Daiichi Sankyo, Inc.

Intervention(s):

  • Drug: Tolbutamide
  • Drug: Midazolam
  • Drug: Pexidartinib

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Is the age of majority in country of residence

   - Has a diagnosis of:

      1. tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity
      or functional limitations and for whom surgery is not an option (prior
      pexidartinib is permitted for TGCT patients unless ineffective or not tolerated
      and there has been a washout period of at least 4 weeks)

      2. KIT-mutant tumor, including melanoma or gastrointestinal stromal tumor (GIST),
      for which there is no standard systemic therapy, or

      3. other solid tumors (all comers) for which there is no standard systemic therapy
      and there is a rationale for use of pexidartinib at the Investigator's discretion

   - If a female of childbearing potential, had a negative serum pregnancy test within 14
   days before enrollment, or within 72 hours before enrollment where required

   - Is a non-sterile male or female willing to use of one of the protocol-defined highly
   effective contraception methods:

      1. intra-uterine device (nonhormonal or hormonal)

      2. sexual abstinence (only if this is in line with the patient's current lifestyle)

      3. barrier methods (eg, condom, diaphragm) used in combination with hormonal methods
      associated with inhibition of ovulation

   - Is a surgically sterile male or female, or is postmenopausal for at least 1 year, at
   least 50 years of age, with a follicle-stimulating hormone level > 40
   milli-International units per mL (mIU/mL)

   - Has adequate hematologic, hepatic, and renal function as defined by the protocol

   - Is able and willing to follow all study procedures

   - Has provided a signed informed consent

Exclusion Criteria:

   - Is pregnant or breastfeeding

   - Is unable to swallow oral medication

   - Is unable to follow study procedures

   - Is taking or has taken any medications or therapies outside of protocol-defined
   parameters

   - Has any disease or condition that, per protocol or in the opinion of the investigator,
   might affect:

      1. safety and well-being of the participant or offspring

      2. safety of study staff

      3. analysis of results

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

This study has two parts.

Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents.

Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types.

In Part 2, the same participants will continue to receive pexidartinib twice daily.

Participants will be allowed to continue using pexidartinib as long as the participant derives benefit.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Daiichi Sankyo, Inc.

Intervention(s):

  • Drug: Tolbutamide
  • Drug: Midazolam
  • Drug: Pexidartinib

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Is the age of majority in country of residence

   - Has a diagnosis of:

      1. tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity
      or functional limitations and for whom surgery is not an option (prior
      pexidartinib is permitted for TGCT patients unless ineffective or not tolerated
      and there has been a washout period of at least 4 weeks)

      2. KIT-mutant tumor, including melanoma or gastrointestinal stromal tumor (GIST),
      for which there is no standard systemic therapy, or

      3. other solid tumors (all comers) for which there is no standard systemic therapy
      and there is a rationale for use of pexidartinib at the Investigator's discretion

   - If a female of childbearing potential, had a negative serum pregnancy test within 14
   days before enrollment, or within 72 hours before enrollment where required

   - Is a non-sterile male or female willing to use of one of the protocol-defined highly
   effective contraception methods:

      1. intra-uterine device (nonhormonal or hormonal)

      2. sexual abstinence (only if this is in line with the patient's current lifestyle)

      3. barrier methods (eg, condom, diaphragm) used in combination with hormonal methods
      associated with inhibition of ovulation

   - Is a surgically sterile male or female, or is postmenopausal for at least 1 year, at
   least 50 years of age, with a follicle-stimulating hormone level > 40
   milli-International units per mL (mIU/mL)

   - Has adequate hematologic, hepatic, and renal function as defined by the protocol

   - Is able and willing to follow all study procedures

   - Has provided a signed informed consent

Exclusion Criteria:

   - Is pregnant or breastfeeding

   - Is unable to swallow oral medication

   - Is unable to follow study procedures

   - Is taking or has taken any medications or therapies outside of protocol-defined
   parameters

   - Has any disease or condition that, per protocol or in the opinion of the investigator,
   might affect:

      1. safety and well-being of the participant or offspring

      2. safety of study staff

      3. analysis of results

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

This study has two parts.

Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents.

Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types.

In Part 2, the same participants will continue to receive pexidartinib twice daily.

Participants will be allowed to continue using pexidartinib as long as the participant derives benefit.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Daiichi Sankyo, Inc.

Intervention(s):

  • Drug: Tolbutamide
  • Drug: Midazolam
  • Drug: Pexidartinib

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Is the age of majority in country of residence

   - Has a diagnosis of:

      1. tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity
      or functional limitations and for whom surgery is not an option (prior
      pexidartinib is permitted for TGCT patients unless ineffective or not tolerated
      and there has been a washout period of at least 4 weeks)

      2. KIT-mutant tumor, including melanoma or gastrointestinal stromal tumor (GIST),
      for which there is no standard systemic therapy, or

      3. other solid tumors (all comers) for which there is no standard systemic therapy
      and there is a rationale for use of pexidartinib at the Investigator's discretion

   - If a female of childbearing potential, had a negative serum pregnancy test within 14
   days before enrollment, or within 72 hours before enrollment where required

   - Is a non-sterile male or female willing to use of one of the protocol-defined highly
   effective contraception methods:

      1. intra-uterine device (nonhormonal or hormonal)

      2. sexual abstinence (only if this is in line with the patient's current lifestyle)

      3. barrier methods (eg, condom, diaphragm) used in combination with hormonal methods
      associated with inhibition of ovulation

   - Is a surgically sterile male or female, or is postmenopausal for at least 1 year, at
   least 50 years of age, with a follicle-stimulating hormone level > 40
   milli-International units per mL (mIU/mL)

   - Has adequate hematologic, hepatic, and renal function as defined by the protocol

   - Is able and willing to follow all study procedures

   - Has provided a signed informed consent

Exclusion Criteria:

   - Is pregnant or breastfeeding

   - Is unable to swallow oral medication

   - Is unable to follow study procedures

   - Is taking or has taken any medications or therapies outside of protocol-defined
   parameters

   - Has any disease or condition that, per protocol or in the opinion of the investigator,
   might affect:

      1. safety and well-being of the participant or offspring

      2. safety of study staff

      3. analysis of results

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

This study has two parts.

Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents.

Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types.

In Part 2, the same participants will continue to receive pexidartinib twice daily.

Participants will be allowed to continue using pexidartinib as long as the participant derives benefit.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Daiichi Sankyo, Inc.

Intervention(s):

  • Drug: Tolbutamide
  • Drug: Midazolam
  • Drug: Pexidartinib

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Is the age of majority in country of residence

   - Has a diagnosis of:

      1. tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity
      or functional limitations and for whom surgery is not an option (prior
      pexidartinib is permitted for TGCT patients unless ineffective or not tolerated
      and there has been a washout period of at least 4 weeks)

      2. KIT-mutant tumor, including melanoma or gastrointestinal stromal tumor (GIST),
      for which there is no standard systemic therapy, or

      3. other solid tumors (all comers) for which there is no standard systemic therapy
      and there is a rationale for use of pexidartinib at the Investigator's discretion

   - If a female of childbearing potential, had a negative serum pregnancy test within 14
   days before enrollment, or within 72 hours before enrollment where required

   - Is a non-sterile male or female willing to use of one of the protocol-defined highly
   effective contraception methods:

      1. intra-uterine device (nonhormonal or hormonal)

      2. sexual abstinence (only if this is in line with the patient's current lifestyle)

      3. barrier methods (eg, condom, diaphragm) used in combination with hormonal methods
      associated with inhibition of ovulation

   - Is a surgically sterile male or female, or is postmenopausal for at least 1 year, at
   least 50 years of age, with a follicle-stimulating hormone level > 40
   milli-International units per mL (mIU/mL)

   - Has adequate hematologic, hepatic, and renal function as defined by the protocol

   - Is able and willing to follow all study procedures

   - Has provided a signed informed consent

Exclusion Criteria:

   - Is pregnant or breastfeeding

   - Is unable to swallow oral medication

   - Is unable to follow study procedures

   - Is taking or has taken any medications or therapies outside of protocol-defined
   parameters

   - Has any disease or condition that, per protocol or in the opinion of the investigator,
   might affect:

      1. safety and well-being of the participant or offspring

      2. safety of study staff

      3. analysis of results

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Maria Ahern
650-725-6413
Recruiting